Ultrasound Methods for Biodiesel Production and Analysis

Ultrasonic techniques have been widely used in biodiesel production, since the acoustic cavitation is a phenomenon capable of accelerating potentially the transesterification reactions. The equipment employed in such approach was simply equipment available in any regular laboratory of chemistry. Further developments introduced the ultrasound as an important tool to produce biodiesel. The main advantage is increasing the conversion of esters at reduced reaction times, with significantly lower production costs. As a method for characterization and analysis of materials, ultrasound has been used since several decades ago. However, ultrasonic analytical methods based on metrological principles are fairly recent investigated. Using ultrasound as physical principle to interrogate biodiesel is a promising field of research, with some remarkable outcomes produced so far. The aim of this chapter is to demonstrate advances of using ultrasonic techniques in production and characterization of biodiesel, as well as an appraisal of the current technology status, and provide insights into future developments

Ultrasound as a Metrological Tool for Monitoring Transesterification Kinetics

Ultrasound has been widely used as a technological alternative way to analyse non-invasively an assortment of materials. It includes liquids with dissimilar physical characteristics, including mono- and multi-phasic mixtures, suspension formation and dissolution, in-line processing, among other practical applications. Regardless the huge spread of uses, so far ultrasound has not been proved to be able to quantify transesterification kinetics with a metrological approach. The aim of this chapter is to demonstrate that a properly designed ultrasonic experiment can be developed to identify remarkable stages of a transesterification reaction to produce biodiesel. The method was compared both with gas chromatography and hydrogen nuclear magnetic resonance (1H NMR). For an in-line application, ultrasound has been proved to work properly as a monitoring tool for chemical reaction kinetics

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362